• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种提议的弥漫性骨髓[18F]-FDG摄取指数及PET骨骼模式与骨髓瘤预后标志物、浆细胞形态及治疗反应相关。

A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy.

作者信息

Paschali A, Panagiotidis E, Triantafyllou T, Palaska V, Tsirou K, Verrou E, Υiannaki E, Markala D, Papanikolaou A, Pouli A, Konstantinidou P, Chatzipavlidou V, Terpos E, Katodritou E

机构信息

Department of Nuclear Medicine, Theagenion Cancer Hospital, Thessaloniki, Greece.

Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece.

出版信息

Eur J Nucl Med Mol Imaging. 2021 May;48(5):1487-1497. doi: 10.1007/s00259-020-05078-1. Epub 2020 Oct 25.

DOI:10.1007/s00259-020-05078-1
PMID:33099659
Abstract

PURPOSE

The investigation of a semi-quantitative index in the pelvis to assess for diffuse bone marrow (BM) [18F]-FDG uptake and the investigation of PET skeletal patterns in multiple myeloma (MM) patients, in accordance with prognostic markers, clonal plasma cell (cPC) morphology, and response to therapy.

METHODS

We prospectively analyzed [18F]-FDG PET/CT in 90 MM patients (newly diagnosed, 60; relapsed/refractory, 30). Among other PET/CT parameters, we calculated the ratio SUVmax pelvis/liver and examined for correlations with known MM prognostic parameters, cPC morphology (good vs. low/intermediate differentiation), and response to therapy.

RESULTS

SUVmax pelvis/liver ratio was significantly lower for the group of good differentiation vs. intermediate/low differentiation cPCs (p < 0.001) and showed a positive correlation with BM infiltration rate, β2 microglobulin, serum ferritin, international staging system (ISS), and revised ISS; no significant correlation was found with hemoglobin. A cutoff value of 1.1 showed an excellent specificity (99%) and high sensitivity (76%) for diffuse BM involvement (AUC 0.94; p < 0.001). Mixed pattern and appendicular involvement correlated with poor prognostic features while normal pattern, found in 30% of patients, correlated with good prognostic features. Presence of ≥ 10 focal lesions negatively predicted for overall response (p < 0.05; OR 4.8). The CT component improved the diagnostic performance of PET.

CONCLUSION

This study showed, for the first time, that cPC morphology and markers related with MM biology, correlate with SUVmax pelvis/liver index, which could be used as a surrogate marker for BM assessment and disease prognosis; PET patterns correlate with MM prognostic features and response rates.

摘要

目的

研究骨盆中的半定量指标,以评估弥漫性骨髓(BM)[18F]-FDG摄取情况,并根据预后标志物、克隆性浆细胞(cPC)形态及治疗反应,研究多发性骨髓瘤(MM)患者的PET骨骼模式。

方法

我们前瞻性分析了90例MM患者(新诊断患者60例,复发/难治性患者30例)的[18F]-FDG PET/CT。在其他PET/CT参数中,我们计算了SUVmax骨盆/肝脏比值,并检查其与已知MM预后参数、cPC形态(高分化与低/中分化)及治疗反应的相关性。

结果

高分化cPC组的SUVmax骨盆/肝脏比值显著低于中/低分化cPC组(p < 0.001),且与骨髓浸润率、β2微球蛋白、血清铁蛋白、国际分期系统(ISS)及修订后的ISS呈正相关;与血红蛋白无显著相关性。截断值为1.1时,对弥漫性骨髓受累具有极佳的特异性(99%)和高敏感性(76%)(AUC 0.94;p < 0.001)。混合模式和四肢受累与不良预后特征相关,而30%的患者出现的正常模式与良好预后特征相关。≥10个局灶性病变的存在对总体反应具有负向预测作用(p < 0.05;OR 4.8)。CT部分提高了PET的诊断性能。

结论

本研究首次表明,cPC形态及与MM生物学相关的标志物与SUVmax骨盆/肝脏指数相关,该指数可作为骨髓评估和疾病预后的替代标志物;PET模式与MM预后特征及反应率相关。

相似文献

1
A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy.一种提议的弥漫性骨髓[18F]-FDG摄取指数及PET骨骼模式与骨髓瘤预后标志物、浆细胞形态及治疗反应相关。
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1487-1497. doi: 10.1007/s00259-020-05078-1. Epub 2020 Oct 25.
2
(18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.(18)F-FDG 动态 PET/CT 检查在多发性骨髓瘤患者中的应用:示踪剂摄取模式及其与骨髓浆细胞浸润率的相关性。
Clin Nucl Med. 2015 Jun;40(6):e300-7. doi: 10.1097/RLU.0000000000000773.
3
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
4
Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.多发性骨髓瘤患者基线18F-FDG PET/CT检查结果与骨髓中表达CD38和CD138的骨髓瘤细胞及临床参数之间的相关性
Turk J Haematol. 2018 Aug 3;35(3):175-180. doi: 10.4274/tjh.2017.0372. Epub 2018 May 28.
5
Prognostic Importance of Bone Marrow Uptake on Baseline F-FDG Positron Emission Tomography in Diffuse Large B Cell Lymphoma.弥漫性大B细胞淋巴瘤患者基线F-FDG正电子发射断层扫描骨髓摄取的预后意义
Cancer Biother Radiopharm. 2016 Dec;31(10):361-365. doi: 10.1089/cbr.2016.2132.
6
C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to F-FDG PET/CT and Prognostic Value.C-蛋氨酸 PET/CT 在多发性骨髓瘤患者评估中的应用:与 F-FDG PET/CT 的比较及预后价值。
Int J Mol Sci. 2022 Aug 31;23(17):9895. doi: 10.3390/ijms23179895.
7
Coefficient of variation and texture analysis of 18F-FDG PET/CT images for the prediction of outcome in patients with multiple myeloma.18F-FDG PET/CT 图像变异系数和纹理分析预测多发性骨髓瘤患者的预后。
Ann Hematol. 2024 Sep;103(9):3713-3721. doi: 10.1007/s00277-024-05905-7. Epub 2024 Jul 24.
8
Bone marrow tracer uptake pattern of PET-CT in multiple myeloma: image interpretation and prognostic value.多发性骨髓瘤患者的 PET-CT 骨髓示踪剂摄取模式:图像解读与预后价值。
Ann Hematol. 2021 Dec;100(12):2979-2988. doi: 10.1007/s00277-021-04629-2. Epub 2021 Aug 20.
9
Pretreatment F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma.初治多发性骨髓瘤患者 F-FDG PET/CT 预处理联合克隆性循环浆细胞定量作为潜在风险模型。
Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1325-1333. doi: 10.1007/s00259-019-4275-5. Epub 2019 Jan 28.
10
11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.11C-乙酰酸盐正电子发射断层扫描比 18F-氟代脱氧葡萄糖正电子发射断层扫描更精确,可用于评估多发性骨髓瘤的肿瘤负担和预测疾病风险。
Sci Rep. 2021 Nov 12;11(1):22188. doi: 10.1038/s41598-021-01740-2.

引用本文的文献

1
Amino Acid and Proliferation PET/CT for the Diagnosis of Multiple Myeloma.用于诊断多发性骨髓瘤的氨基酸与增殖PET/CT
Front Nucl Med. 2022 Jan 6;1:796357. doi: 10.3389/fnume.2021.796357. eCollection 2021.
2
Clinical value of F-FDG PET/CT in patients with newly diagnosed acute leukemia.F-FDG PET/CT在新诊断急性白血病患者中的临床价值
Cell Oncol (Dordr). 2024 Dec;47(6):2135-2145. doi: 10.1007/s13402-024-00993-z. Epub 2024 Sep 24.
3
IMPeTUs parameters correlate with clinical features in newly diagnosed multiple myeloma.

本文引用的文献

1
F-FDG PET or PET/CT in Mantle Cell Lymphoma.弥漫大 B 细胞淋巴瘤的 F-FDG PET 或 PET/CT。
Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):422-430. doi: 10.1016/j.clml.2020.01.018. Epub 2020 Feb 4.
2
Proposal for a Quantitative F-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma.用于评估多发性骨髓瘤骨受累程度的定量 F-FDG PET/CT 代谢参数的提案。
Sci Rep. 2019 Nov 11;9(1):16429. doi: 10.1038/s41598-019-52740-2.
3
Low hexokinase-2 expression-associated false-negative F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma.
IMPeTUs参数与新诊断多发性骨髓瘤的临床特征相关。
Eur J Radiol Open. 2024 Sep 3;13:100598. doi: 10.1016/j.ejro.2024.100598. eCollection 2024 Dec.
4
DCE-MRI to distinguish all monoclonal plasma cell disease stages and correlation with diffusion-weighted MRI/PET-based biomarkers in a hybrid simultaneous whole body-2-[18F]FDG-PET/MRI imaging approach.DCE-MRI 用于区分所有单克隆浆细胞疾病阶段,并与基于扩散加权 MRI/PET 的生物标志物在混合式同步全身 2-[18F]FDG-PET/MRI 成像方法中的相关性。
Cancer Imaging. 2024 Jul 11;24(1):93. doi: 10.1186/s40644-024-00740-5.
5
Prognostic value of visual IMPeTUs criteria and metabolic tumor burden at baseline [F]FDG PET/CT in patients with newly diagnosed multiple myeloma.视觉IMPeTUs标准及基线[F]FDG PET/CT代谢肿瘤负荷对新诊断多发性骨髓瘤患者的预后价值
EJNMMI Res. 2024 May 28;14(1):51. doi: 10.1186/s13550-024-01113-6.
6
Hybrid simultaneous whole-body 2-[F]FDG-PET/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results.新型多发性骨髓瘤患者的 Hybrid 同步全身 2-[F]FDG-PET/MRI 成像:初步诊断性能和临床附加价值结果。
Eur Radiol. 2023 Sep;33(9):6438-6447. doi: 10.1007/s00330-023-09593-1. Epub 2023 Apr 6.
7
C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to F-FDG PET/CT and Prognostic Value.C-蛋氨酸 PET/CT 在多发性骨髓瘤患者评估中的应用:与 F-FDG PET/CT 的比较及预后价值。
Int J Mol Sci. 2022 Aug 31;23(17):9895. doi: 10.3390/ijms23179895.
8
Progress of modern imaging modalities in multiple myeloma.多发性骨髓瘤的现代影像学进展。
Int J Hematol. 2022 Jun;115(6):778-789. doi: 10.1007/s12185-022-03360-6. Epub 2022 May 9.
低己糖激酶-2 表达相关的 F-FDG PET/CT 假阴性作为多发性骨髓瘤患者的潜在预后预测指标。
Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1345-1350. doi: 10.1007/s00259-019-04312-9. Epub 2019 Mar 22.
4
Hexokinase-2 Expression in C-Methionine-Positive, F-FDG-Negative Multiple Myeloma.C-蛋氨酸阳性、F-FDG 阴性多发性骨髓瘤中己糖激酶-2 的表达。
J Nucl Med. 2019 Mar;60(3):348-352. doi: 10.2967/jnumed.118.217539. Epub 2018 Nov 2.
5
Prognostic factors for multiple myeloma in the era of novel therapies.新型疗法时代多发性骨髓瘤的预后因素。
Expert Rev Hematol. 2018 Nov;11(11):863-879. doi: 10.1080/17474086.2018.1537776. Epub 2018 Oct 26.
6
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group.多发性骨髓瘤和其他浆细胞疾病患者全身低剂量 CT 采集、解读和报告的推荐:IMWG 骨骼工作组的报告。
Blood Cancer J. 2018 Oct 4;8(10):95. doi: 10.1038/s41408-018-0124-1.
7
Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma.初诊多发性骨髓瘤患者 F-FDG 正电子发射断层扫描/计算机断层扫描的效用和预后价值。
Am J Hematol. 2018 Dec;93(12):1518-1523. doi: 10.1002/ajh.25279. Epub 2018 Oct 2.
8
Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma.多发性骨髓瘤患者四肢骨骼骨髓异常的预后意义。
Blood Adv. 2018 May 8;2(9):1032-1039. doi: 10.1182/bloodadvances.2017014720.
9
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).FDG PET/CT 多发性骨髓瘤解读标准(IMPeTUs):最终结果。IMPeTUs(意大利多发性骨髓瘤 PET 使用标准)。
Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719. doi: 10.1007/s00259-017-3909-8. Epub 2017 Dec 21.
10
Prospective Evaluation of Magnetic Resonance Imaging and [F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.IFM/DFCI 2009试验中纳入的有症状多发性骨髓瘤患者在诊断时及维持治疗前进行磁共振成像和[F]氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描的前瞻性评估:IMAJEM研究结果
J Clin Oncol. 2017 Sep 1;35(25):2911-2918. doi: 10.1200/JCO.2017.72.2975. Epub 2017 Jul 7.